Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market
01 mai 2024 14h17 HE
|
Spherix Global Insights
EXTON, PA, May 01, 2024 (GLOBE NEWSWIRE) -- In the landscape of healthcare innovation, retinal disorders, including both inherited and degenerative diseases, have become a leading focus area for...
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
01 mai 2024 07h30 HE
|
Atsena Therapeutics
Subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in two patients Provides evidence that AAV.SPR spreads laterally...
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
30 avr. 2024 08h38 HE
|
Fractyl Health, Inc.
Fractyl Health Announces Multiple Presentations at DDW 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
Global Cell & Gene Therapy Cold Chain Logistics Market Outlook, 2024-2029: Surge in Collaborations and Patient-Centric Logistics for Personalized Therapies Driving the Market at 14.1% CAGR
30 avr. 2024 04h03 HE
|
Research and Markets
Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Cell & Gene Therapy Cold Chain Logistics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F" report has been added...
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
29 avr. 2024 06h45 HE
|
Ocugen
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
26 avr. 2024 09h05 HE
|
Ocugen
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Global Cell and Gene Therapies in Hemophilia A & B Analysis Report 2024: Market to Reach $2.2 Billion by 2029 - Major Players Are Expected To Intensify Competition
26 avr. 2024 07h22 HE
|
Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapies in Hemophilia A & B" report has been added to ResearchAndMarkets.com's offering. The global hemophilia A and B CGT...
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
26 avr. 2024 06h30 HE
|
Ocugen
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
25 avr. 2024 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
Gene Therapy For Ocular Rare Disease Pipeline Insight Report 2024
25 avr. 2024 04h06 HE
|
Research and Markets
Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy For Ocular Rare Disease - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.The report provides...